Non-OC (n = 54) | OC (n = 17) | P value | |
---|---|---|---|
Baseline characteristics | |||
Age (year) | 73 (65–78) | 71 (67–76) | 0.576 |
Male (N (%)) | 30 (55.6) | 9 (52.9) | 0.850 |
Serum albumin (mg/dL) | 3.0 (2.3–3.7) | 2.8 (2.2–3.2) | 0.138 |
Serum creatinine (mg/dL) | 0.9 (0.7–1.7) | 1.2 (0.5–2.1) | 0.925 |
CRP (mg/dL) | 3.3 (0.9–9.0) | 4.8 (2.7–9.4) | 0.196 |
IgG (mg/dL) | 1682 (1403–2046) | 1674 (1170–1992) | 0.454 |
Diagnosis | |||
MPA | 45 (83.3) | 13 (76.5) | 0.196 |
GPA | 0 (0.0) | 1 (5.9) | |
EGPA | 9 (16.7) | 3 (17.6) | |
Antibody | |||
MPO-ANCA | 50 (92.6) | 17 (100) | 0.513 |
PR3-ANCA | 1 (1.9) | 0 (0) | |
ANCA-negative | 3 (5.6) | 0 (0) | |
BVAS | 13 (11–16) | 15 (13–16) | 0.183 |
General | 52 (96.3) | 17 (100) | 0.421 |
Cutaneous | 6 (11.1) | 5 (29.4) | 0.069 |
Ear, nose, and throat | 11 (20.4) | 6 (35.3) | 0.209 |
Chest | 26 (48.2) | 6 (35.3) | 0.353 |
Cardiovascular | 1 (1.9) | 1 (5.9) | 0.381 |
Abdominal | 3 (5.6) | 0 (0) | 0.321 |
Renal | 28 (51.9) | 10 (58.8) | 0.615 |
Nervous system | 17 (31.5) | 8 (47.1) | 0.241 |
Induction immunosupressive therapy | |||
Glucocorticoid monotherapy | 45 (83.3) | 14 (82.4) | 0.939 |
Intravenous cyclophosphamide | 5 (9.3) | 2 (11.8) | |
Rituximab | 4 (7.4) | 1 (5.9) | |
Use of mPSL pulse therapy | 18 (33.3) | 8 (47.6) | 0.306 |
Maintenance immunosuppressive therapy | |||
Glucocorticoid monotherapy | 34 (63.0) | 9 (52.9) | 0.863 |
Oral cyclophosphamide | 2 (3.7) | 1 (5.9) | |
Azathioprine | 13 (24.1) | 5 (29.4) | |
Methotrexate | 1 (1.9) | 1 (5.9) | |
Rituximab | 4 (7.4) | 1 (5.9) | |
Outcomes | |||
Remission | 52 (96.3) | 15 (88.2) | 0.209 |
Relapse | 19 (38.0) | 10 (62.5) | 0.086 |
Hemodialysis | 2 (3.7) | 2 (11.8) | 0.209 |
Deaths | 4 (7.4) | 1 (5.9) | 0.830 |
Severe Infection | 8 (14.8) | 11 (64.7) | < 0.001 |
Observation period (months) | 26 (12–51) | 15 (5–47) | 0.396 |